1-7 of 7
Christophe Bouvier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life” Settings: A Population-Based Study Using a Nationwide Claim Database

Meriem Benmerad, Jules Chassetuillier, Christophe Bouvier, Pierre-Louis Lecoq, Romain Favier, Matthieu Trancart, Sandrine Hayette, Julien Bollard, Audrey Lajoinie, Franck E. Nicolini
Journal: Blood
Blood (2023) 142 (Supplement 1): 3174.
https://doi.org/10.1182/blood-2023-178703
Published: 2023
Journal Articles

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Jules Chassetuillier, Meriem Benmerad, Pierre-Louis Lecoq, Romain Favier, Matthieu Trancart, Sandrine Hayette, Vincent Alcazer, Christophe Bouvier, Julien Bollard, Audrey Lajoinie, Franck E. Nicolini
Journal: Blood
Blood (2023) 142 (Supplement 1): 6369.
https://doi.org/10.1182/blood-2023-179970
Published: 2023
Journal Articles

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Maria Agustina Perusini, Camille Kockerols, Daniela Žáčková, Franck E. Nicolini, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Mary Lynn Savoie, Christophe Bouvier, Petra Čičátková, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Jiří Mayer, Peter E Westerweel, Dennis Dong Hwan Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 6360.
https://doi.org/10.1182/blood-2023-190293
Published: 2023
Journal Articles

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Franck E. Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Stéphanie Dulucq, Sandrine Hayette, Stéphane Morisset, Rachel Parat, Christophe Bouvier, Gabriel Etienne
Journal: Blood
Blood (2022) 140 (Supplement 1): 3918–3919.
https://doi.org/10.1182/blood-2022-163376
Published: 2022
Journal Articles

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Franck E. Nicolini, Francoise Huguet, Lynn Huynh, Churong Xu, Christophe Bouvier, Aurore Yocolly, Gabriel Etienne
Journal: Blood
Blood (2022) 140 (Supplement 1): 9656–9658.
https://doi.org/10.1182/blood-2022-160268
Published: 2022
Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea
Journal: Blood
Blood (2021) 138 (Supplement 1): 2552.
https://doi.org/10.1182/blood-2021-146722
Published: 2021
Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-139921
Published: 2020